<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35532908</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.</ArticleTitle><Pagination><StartPage>575</StartPage><EndPage>583</EndPage><MedlinePgn>575-583</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2022.0901</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The effectiveness of currently approved drugs for amyotrophic lateral sclerosis (ALS) is restricted; there is a need to develop further treatments. Initial studies have shown ultrahigh-dose methylcobalamin to be a promising agent.</AbstractText><AbstractText Label="OBJECTIVE">To validate the efficacy and safety of ultrahigh-dose methylcobalamin for patients with ALS enrolled within 1 year of onset.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This was a multicenter, placebo-controlled, double-blind, randomized phase 3 clinical trial with a 12-week observation and 16-week randomized period, conducted from October 17, 2017, to September 30, 2019. Patients were recruited from 25 neurology centers in Japan; those with ALS diagnosed within 1 year of onset by the updated Awaji criteria were initially enrolled. Of those, patients fulfilling the following criteria after 12-week observation were eligible for randomization: 1- or 2-point decrease in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) total score, a percent forced vital capacity greater than 60%, no history of noninvasive respiratory support and tracheostomy, and being ambulatory. The target participant number was 64 in both the methylcobalamin and placebo groups. Patients were randomly assigned through an electronic web-response system to methylcobalamin or placebo.</AbstractText><AbstractText Label="INTERVENTIONS">Intramuscular injection of methylcobalamin (50-mg dose) or placebo twice weekly for 16 weeks.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary end point was change in ALSFRS-R total score from baseline to week 16 in the full analysis set.</AbstractText><AbstractText Label="RESULTS">A total of 130 patients (mean [SD] age, 61.0&#x2009;[11.7] years; 74 men [56.9%]) were randomly assigned to methylcobalamin or placebo (65 each). A total of 129 patients were eligible for the full analysis set, and 126 completed the double-blind stage. Of these, 124 patients proceeded to the open-label extended period. The least square means difference in ALSFRS-R total score at week 16 of the randomized period was 1.97 points greater with methylcobalamin than placebo (-2.66 vs -4.63; 95% CI, 0.44-3.50; P&#x2009;=&#x2009;.01). The incidence of adverse events was similar between the 2 groups.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Results of this randomized clinical trial showed that ultrahigh-dose methylcobalamin was efficacious in slowing functional decline in patients with early-stage ALS and with moderate progression rate and was safe to use during the 16-week treatment period.</AbstractText><AbstractText Label="TRIAL REGISTRATION">ClinicalTrials.gov Identifier: NCT03548311.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oki</LastName><ForeName>Ryosuke</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Izumi</LastName><ForeName>Yuishin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujita</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyamoto</LastName><ForeName>Ryosuke</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nodera</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Yasutaka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakaguchi</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nokihara</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanai</LastName><ForeName>Kazuaki</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Fukushima Medical University School of Medicine, Fukushima, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsunemi</LastName><ForeName>Taiji</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hattori</LastName><ForeName>Nobutaka</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hatanaka</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Teikyo University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sonoo</LastName><ForeName>Masahiro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Teikyo University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atsuta</LastName><ForeName>Naoki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sobue</LastName><ForeName>Gen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimizu</LastName><ForeName>Toshio</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokyo Metropolitan Neurological Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shibuya</LastName><ForeName>Kazumoto</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Chiba University Graduate School of Medicine, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikeda</LastName><ForeName>Ken</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Toho University Faculty of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kano</LastName><ForeName>Osamu</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neurology, Toho University Faculty of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishinaka</LastName><ForeName>Kazuto</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sumitomo Hospital, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kojima</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Takeda General Hospital, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oda</LastName><ForeName>Masaya</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Vihara Hananosato Hospital, Miyoshi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Komai</LastName><ForeName>Kiyonobu</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, National Hospital Organization Iou Hospital, Kanazawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kikuchi</LastName><ForeName>Hitoshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Murakami Karindoh Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kohara</LastName><ForeName>Nobuo</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kobe City Medical Center General Hospital, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urushitani</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Shiga University of Medical Science, Otsu, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakayama</LastName><ForeName>Yoshiaki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Wakayama Medical University, Wakayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Hidefumi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Wakayama Medical University, Wakayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagai</LastName><ForeName>Makiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kitasato University School of Medicine, Sagamihara, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishiyama</LastName><ForeName>Kazutoshi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kitasato University School of Medicine, Sagamihara, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuzume</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Chikamori Hospital, Kochi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimohama</LastName><ForeName>Shun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sapporo Medical University, Sapporo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimohata</LastName><ForeName>Takayoshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Gifu University Graduate School of Medicine, Gifu, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abe</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishihara</LastName><ForeName>Tomohiko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brain Research Institute, Niigata University, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Onodera</LastName><ForeName>Osamu</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brain Research Institute, Niigata University, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isose</LastName><ForeName>Sagiri</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, National Hospital Organization Chibahigashi Hospital, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Araki</LastName><ForeName>Nobuyuki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, National Hospital Organization Chibahigashi Hospital, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morita</LastName><ForeName>Mitsuya</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Internal Medicine, Jichi Medical University, Shimotsuke, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noda</LastName><ForeName>Kazuyuki</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Juntendo University Shizuoka Hospital, Izunokuni, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toda</LastName><ForeName>Tatsushi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maruyama</LastName><ForeName>Hirofumi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furuya</LastName><ForeName>Hirokazu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kochi Medical School, Kochi University, Nankoku, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teramukai</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kagimura</LastName><ForeName>Tatsuo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Translational Research Center for Medical Innovation, Foundation for Biomedical Research and Innovation, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noma</LastName><ForeName>Kensuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Regeneration and Medicine, Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiovascular Regeneration and Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yanagawa</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuwabara</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Chiba University Graduate School of Medicine, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaji</LastName><ForeName>Ryuji</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, National Hospital Organization Utano Hospital, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Japan Early-Stage Trial of Ultrahigh-Dose Methylcobalamin for ALS (JETALS) Collaborators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03548311</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>BR1SN1JS2W</RegistryNumber><NameOfSubstance UI="C019476">mecobalamin</NameOfSubstance></Chemical><Chemical><RegistryNumber>P6YC3EG204</RegistryNumber><NameOfSubstance UI="D014805">Vitamin B 12</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014797" MajorTopicYN="N">Vital Capacity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014805" MajorTopicYN="N">Vitamin B 12</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Oki reported receiving grants from the Japan Agency for Medical Research and Development and nonfinancial support from Eisai Co Ltd during the conduct of the study. Dr Izumi reported receiving grants from Japan Agency for Medical Research and Development, the Ministry of Health, Labor, and Welfare, Takeda Pharmaceutical Company Limited, and Sumitomo Dainippon Pharma Company Limited outside the submitted work. Dr Fujita reported receiving grants from the Japan Agency for Medical Research and nonfinancial support from Eisai Co Ltd during the conduct of the study. Dr Miyamoto reported receiving grants from the Japan Agency for Medical Research and Development and nonfinancial support from Eisai Co Ltd during the conduct of the study. Dr Nodera reported receiving grants from the Japan Agency for Medical Research and nonfinancial support from Eisai Co Ltd during the conduct of the study. Dr Sato reported receiving grants from the Japan Agency for Medical Research and Development during the conduct of the study. Dr Sakaguchi reported receiving grants from the Japan Agency for Medical Research and Development during the conduct of the study. Dr Nokihara reported receiving grants from the Japan Agency for Medical Research and Development and nonfinancial support from Eisai Co Ltd, personal fees from Eisai Co Ltd, and honoraria for lectures outside the submitted work. Dr Kanai reported receiving grants from the Japan Agency for Medical Research and nonfinancial support from Eisai Co Ltd during the conduct of the study and grants from Grants-in-Aid for Scientific Research outside the submitted work. Dr Tsunemi reported receiving grants from the Japan Agency for Medical Research and nonfinancial support from Eisai Co Ltd and the Ministry of Health, Labor, and Welfare outside the submitted work. Dr Hattori reported receiving grants from the Japan Agency for Medical Research and nonfinancial support from Eisai Co Ltd and the Japan Society for the Promotion of Science, the Japan Agency for Medical Research and Development, and the Japan Science and Technology Agency, Health, and Labor; and personal fees from Sumitomo Dainippon, Takeda, Kyowa Kirin, Teijin, Novartis, Ono, Biogen, Kissei, Mitsubishi Tanabe, Hisamitsu, PARKINSON Laboratories, AbbVie, Nippon Boehringer Ingelheim, Otsuka, Bristol Myers Squibb, FP, Kissei, Nihon Medi-Physics, Daiichi-Sankyo, and Riken outside the submitted work. Dr Atsuta reported receiving grants from the Japan Agency for Medical Research and Development and nonfinancial support from Eisai Co Ltd and the Ministry of Health, Labor, and Welfare; and personal fees from Biogen, Mitsubishi Tanabe, Sumitomo Dainippon, Takeda, Novartis, and Sanofi outside the submitted work. Dr Sobue reported receiving grants from the Japan Agency for Medical Research and Development and nonfinancial support from Eisai Co Ltd during the conduct of the study; personal fees from Mitsubishi Tanabe, Sumitomo Dainippon, Nihon Pharmaceutical, Biogen, Takeda; and grants from the Japan Agency for Medical Research and Development outside the submitted work. Dr Shimizu reported receiving grants from the Japan Agency for Medical Research and Development and nonfinancial support from Eisai Co Ltd during the conduct of the study. Dr Shibuya reported receiving grants from the Japan Agency for Medical Research and Development and nonfinancial support from Eisai Co Ltd during the conduct of the study. Dr Ikeda reported receiving grants from the Japan Agency for Medical Research and Development and nonfinancial support from Eisai Co Ltd during the conduct of the study. Dr Kano reported receiving grants from the Japan Agency for Medical Research and Development and nonfinancial support from Eisai Co Ltd during the conduct of the study. Dr Nishinaka reported receiving grants from the Japan Agency for Medical Research and Development and nonfinancial support from Eisai Co Ltd during the conduct of the study. Dr Kojima reported receiving grants from the Japan Agency for Medical Research and Development and nonfinancial support from Eisai Co Ltd during the conduct of the study. Dr Oda reported receiving grants from the Japan Agency for Medical Research and Development and grants and nonfinancial support from Eisai Co Ltd during the conduct of the study. Dr Komai reported receiving grants from the Japan Agency for Medical Research and Development and nonfinancial support from Eisai Co Ltd during the conduct of the study. Dr Kikuchi reported receiving grants from the Japan Agency for Medical Research and Development during the conduct of the study and nonfinancial support from Eisai Co Ltd outside the submitted work. Dr Kohara reported receiving grants from the Japan Agency for Medical Research and Development and nonfinancial support from Eisai Co Ltd during the conduct of the study. Dr Urushitani reported receiving grants from the Japan Agency for Medical Research and Development during the conduct of the study. Dr Nakayama reported receiving grants from the Japan Agency for Medical Research and Development and nonfinancial support from Eisai Co Ltd during the conduct of the study. Dr Nagai reported receiving grants from the Japan Agency for Medical Research and Development and nonfinancial support from Eisai Co Ltd during the conduct of the study. Dr Nishiyama reported receiving grants from the Japan Agency for Medical Research and Development and nonfinancial support from Eisai Co Ltd during the conduct of the study. Dr Kuzume reported receiving grants from the Japan Agency for Medical Research and Development and nonfinancial support from Eisai Co Ltd during the conduct of the study. Dr Shimohama reported receiving grants from the Japan Agency for Medical Research and Development and nonfinancial support from Eisai Co Ltd during the conduct of the study. Dr Shimohata reported receiving grants from the Japan Agency for Medical Research and Development and nonfinancial support from Eisai Co Ltd during the conduct of the study. Dr Abe reported receiving grants from the Japan Agency for Medical Research and Development and nonfinancial support from Eisai Co Ltd during the conduct of the study. Dr Ishihara reported receiving grants from the Japan Agency for Medical Research and Development, Alexion Pharmaceuticals, and Mitsubishi Tanabe Pharma Development America and nonfinancial support from Eisai Co Ltd outside the submitted work. Dr Onodera reported receiving grants from the Japan Agency for Medical Research and Development and nonfinancial support from Eisai Co Ltd during the conduct of the study. Dr Isose reported receiving grants from the Japan Agency for Medical Research and Development and nonfinancial support from Eisai Co Ltd during the conduct of the study. Dr Araki reported receiving grants from the Japan Agency for Medical Research and Development and nonfinancial support from Eisai Co Ltd during the conduct of the study. Dr Morita reported receiving grants from the Japan Agency for Medical Research and Development and nonfinancial support from Eisai Co Ltd during the conduct of the study. Dr Noda reported receiving grants from the Japan Agency for Medical Research and Development and nonfinancial support from Eisai Co Ltd during the conduct of the study. Dr Maruyama reported receiving personal fees from Eisai Co Ltd, Pfizer, Takeda Pharmaceutical, Otsuka Pharmaceutical, Nihon Pharmaceutical, Teijin Pharma, Sumitomo Dainippon Pharma, Daiichi-Sankyo, Kyowa Kirin, Novartis, Mitsubishi Tanabe Pharma, Ono Pharmaceutical, Biogen, Bristol Myers Squibb, AbbVie GK, Chugai Pharmaceutical, CSL Behring, UCB Japan, Alexion Pharmaceuticals, Amgen, Boehringer Ingelheim, Bayer, and MSD, and grants from Grants-in-Aid for Scientific Research, Eisai Co Ltd, Takeda Pharmaceutical, Otsuka Pharmaceutical, Nihon Pharmaceutical, Shionogi, Teijin Pharma, Fuji Film, Sumitomo Dainippon Pharma, Nihon Medi-Physics, Daiichi-Sankyo, Kyowa Kirin, Sanofi, Novartis, Tsumura, Japan Blood Products Organization, Pfizer, Astellas Pharma, and Mitsubishi Tanabe Pharma outside the submitted work. Dr Teramukai reported receiving personal fees from Daiichi-Sankyo, Takeda Pharmaceutical, Chugai Pharmaceutical, Bayer Yakuhin, and Sanofi outside the submitted work. Dr Kagimura reported receiving grants from the Japan Agency for Medical Research and Development during the conduct of the study. Dr Yanagawa reported receiving grants from the Japan Agency for Medical Research and Development during the conduct of the study. Dr Kaji reported receiving test drug supply from Eisai Co Ltd, and grants from the Japanese Ministry of Health, Labor, and Welfare and the Japan Agency for Medical Research and Development. No other disclosures were reported.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Osaki</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yamazaki</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haji</LastName><ForeName>Shotaro</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ishida</LastName><ForeName>Yumi</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Futami</LastName><ForeName>Akari</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miyamoto</LastName><ForeName>Toshiko</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Akaishi</LastName><ForeName>Akiyo</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Takechi</LastName><ForeName>Kenshi</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maeda</LastName><ForeName>Kazuki</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kurisu</LastName><ForeName>Shoko</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yoshizawa</LastName><ForeName>Mari</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matsuda</LastName><ForeName>Nozomu</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nakazato</LastName><ForeName>Tomoko</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Ryoichi</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hayashi</LastName><ForeName>Naoki</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kawata</LastName><ForeName>Akihiro</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kimura</LastName><ForeName>Hideki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bokuda</LastName><ForeName>Kota</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tamura</LastName><ForeName>Akiko</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ishida</LastName><ForeName>Chiho</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kawamoto</LastName><ForeName>Michi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyo</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kawamata</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hisahara</LastName><ForeName>Shin</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kimura</LastName><ForeName>Yuichi</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yamashita</LastName><ForeName>Toru</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ohta</LastName><ForeName>Yasuyuki</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arai</LastName><ForeName>Kimihito</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Takeda</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ogawa</LastName><ForeName>Tomoo</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ikari</LastName><ForeName>Shingo</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ono</LastName><ForeName>Yasunori</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fujino</LastName><ForeName>Yukio</ForeName><Initials>Y</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>9</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35532908</ArticleId><ArticleId IdType="pmc">PMC9086935</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2022.0901</ArticleId><ArticleId IdType="pii">2792228</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chi&#xf2; A, Logroscino G, Hardiman O, et al. ; Eurals Consortium . Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10(5-6):310-323. doi:10.3109/17482960802566824</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4(3):191-206. doi:10.1080/14660820310002601</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820310002601</ArticleId><ArticleId IdType="pubmed">13129806</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Al Khleifat A, Meurgey JH, et al. . Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018;17(5):416-422. doi:10.1016/S1474-4422(18)30054-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30054-1</ArticleId><ArticleId IdType="pmc">PMC5899963</ArticleId><ArticleId IdType="pubmed">29525492</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Aoki M, Tsuji S, et al. ; Writing Group; Edaravone (MCI-186) ALS 19 Study Group . Safety and efficacy of edaravone in well-defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505-512. doi:10.1016/S1474-4422(17)30115-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K, Iwasaki Y, Kaji R. Neuroprotective effect of ultrahigh-dose methylcobalamin in wobbler mouse model of amyotrophic lateral sclerosis. J Neurol Sci. 2015;354(1-2):70-74. doi:10.1016/j.jns.2015.04.052</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2015.04.052</ArticleId><ArticleId IdType="pubmed">25982504</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaji R, Kodama M, Imamura A, et al. . Effect of ultrahigh-dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: a double-blind controlled study. Muscle Nerve. 1998;21(12):1775-1778. doi:10.1002/(SICI)1097-4598(199812)21:12&lt;1775::AID-MUS22&gt;3.0.CO;2-V</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4598(199812)21:12&lt;1775::AID-MUS22&gt;3.0.CO;2-V</ArticleId><ArticleId IdType="pubmed">9843082</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaji R, Imai T, Iwasaki Y, et al. . Ultrahigh-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II/III randomised controlled study. J Neurol Neurosurg Psychiatry. 2019;90(4):451-457. doi:10.1136/jnnp-2018-319294</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319294</ArticleId><ArticleId IdType="pmc">PMC6581107</ArticleId><ArticleId IdType="pubmed">30636701</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe H, Atsuta N, Hirakawa A, et al. . A rapid functional decline type of amyotrophic lateral sclerosis is linked to low expression of TTN. J Neurol Neurosurg Psychiatry. 2016;87(8):851-858. doi:10.1136/jnnp-2015-311541</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-311541</ArticleId><ArticleId IdType="pubmed">26746183</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Talbot K, et al. . Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol. 2021;17(2):104-118. doi:10.1038/s41582-020-00434-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-00434-z</ArticleId><ArticleId IdType="pmc">PMC7747476</ArticleId><ArticleId IdType="pubmed">33340024</ArticleId></ArticleIdList></Reference><Reference><Citation>Oki R, Izumi Y, Nodera H, et al. ; JETALS . The Japanese Early-Stage Trial of High-Dose Methylcobalamin for Amyotrophic Lateral Sclerosis (JETALS): protocol for a randomized controlled trial. JMIR Res Protoc. 2018;7(12):e12046. doi:10.2196/12046</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/12046</ArticleId><ArticleId IdType="pmc">PMC6320396</ArticleId><ArticleId IdType="pubmed">30578206</ArticleId></ArticleIdList></Reference><Reference><Citation>Geevasinga N, Loy CT, Menon P, et al. . Awaji criteria improves the diagnostic sensitivity in amyotrophic lateral sclerosis: a systematic review using individual patient data. Clin Neurophysiol. 2016;127(7):2684-2691. doi:10.1016/j.clinph.2016.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2016.04.005</ArticleId><ArticleId IdType="pubmed">27212114</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkelstein JD. The metabolism of homocysteine: pathways and regulation. Eur J Pediatr. 1998;157(2)(suppl 2):S40-S44. doi:10.1007/PL00014300</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/PL00014300</ArticleId><ArticleId IdType="pubmed">9587024</ArticleId></ArticleIdList></Reference><Reference><Citation>Castrillo-Viguera C, Grasso DL, Simpson E, Shefner J, Cudkowicz ME. Clinical significance in the change of decline in ALSFRS-R. Amyotroph Lateral Scler. 2010;11(1-2):178-180. doi:10.3109/17482960903093710</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960903093710</ArticleId><ArticleId IdType="pubmed">19634063</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito S, Izumi Y, Niidome T, Ono Y. Methylcobalamin prevents mutant superoxide dismutase-1-induced motor neuron death in vitro. Neuroreport. 2017;28(2):101-107. doi:10.1097/WNR.0000000000000716</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WNR.0000000000000716</ArticleId><ArticleId IdType="pubmed">27922548</ArticleId></ArticleIdList></Reference><Reference><Citation>Obeid R, Herrmann W. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett. 2006;580(13):2994-3005. doi:10.1016/j.febslet.2006.04.088</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2006.04.088</ArticleId><ArticleId IdType="pubmed">16697371</ArticleId></ArticleIdList></Reference><Reference><Citation>Liakishev AA. Homocysteine lowering with folic acid and B vitamins in vascular disease. Article in Russian. Kardiologiia. 2006;46(5):70. doi:10.1016/S0749-4041(08)70686-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0749-4041(08)70686-9</ArticleId><ArticleId IdType="pubmed">16858361</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith AD. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int J Geriatr Psychiatry. 2012;27(6):592-600. doi:10.1002/gps.2758</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.2758</ArticleId><ArticleId IdType="pubmed">21780182</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemendinger RA, Armstrong EJ III, Brooks BR. Methyl vitamin B12, but not methylfolate, rescues a motor neuron-like cell line from homocysteine-mediated cell death. Toxicol Appl Pharmacol. 2011;251(3):217-225. doi:10.1016/j.taap.2011.01.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.taap.2011.01.003</ArticleId><ArticleId IdType="pubmed">21237187</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoccolella S, Bendotti C, Beghi E, Logroscino G. Homocysteine levels and amyotrophic lateral sclerosis: a possible link. Amyotroph Lateral Scler. 2010;11(1-2):140-147. doi:10.3109/17482960902919360</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960902919360</ArticleId><ArticleId IdType="pubmed">19551535</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoccolella S, Simone IL, Lamberti P, et al. . Elevated plasma homocysteine levels in patients with amyotrophic lateral sclerosis. Neurology. 2008;70(3):222-225. doi:10.1212/01.wnl.0000297193.53986.6f</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000297193.53986.6f</ArticleId><ArticleId IdType="pubmed">18195267</ArticleId></ArticleIdList></Reference><Reference><Citation>Hainsworth AH, Yeo NE, Weekman EM, Wilcock DM. Homocysteine, hyperhomocysteinemia and vascular contributions to cognitive impairment and dementia (VCID). Biochim Biophys Acta. 2016;1862(5):1008-1017. doi:10.1016/j.bbadis.2015.11.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2015.11.015</ArticleId><ArticleId IdType="pmc">PMC4821788</ArticleId><ArticleId IdType="pubmed">26689889</ArticleId></ArticleIdList></Reference><Reference><Citation>Birch CS, Brasch NE, McCaddon A, Williams JHH. A novel role for vitamin B(12): cobalamins are intracellular antioxidants in vitro. Free Radic Biol Med. 2009;47(2):184-188. doi:10.1016/j.freeradbiomed.2009.04.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2009.04.023</ArticleId><ArticleId IdType="pubmed">19409980</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez-Moreira E, Yun J, Birch CS, Williams JHH, McCaddon A, Brasch NE. Vitamin B(12) and redox homeostasis: cob(II)alamin reacts with superoxide at rates approaching superoxide dismutase (SOD). J Am Chem Soc. 2009;131(42):15078-15079. doi:10.1021/ja904670x</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja904670x</ArticleId><ArticleId IdType="pubmed">19799418</ArticleId></ArticleIdList></Reference><Reference><Citation>Akaike A, Tamura Y, Sato Y, Yokota T. Protective effects of a vitamin B12 analog, methylcobalamin, against glutamate cytotoxicity in cultured cortical neurons. Eur J Pharmacol. 1993;241(1):1-6. doi:10.1016/0014-2999(93)90925-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-2999(93)90925-8</ArticleId><ArticleId IdType="pubmed">7901032</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacher E, Bashiardes S, Shapiro H, et al. . Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature. 2019;572(7770):474-480. doi:10.1038/s41586-019-1443-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1443-5</ArticleId><ArticleId IdType="pubmed">31330533</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Huang T, Debelius JW, Fang F. Gut microbiome and amyotrophic lateral sclerosis: a systematic review of current evidence. J Intern Med. 2021;290(4):758-788. doi:10.1111/joim.13336</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13336</ArticleId><ArticleId IdType="pubmed">34080741</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfohl-Leszkowicz A, Keith G, Dirheimer G. Effect of cobalamin derivatives on in vitro enzymatic DNA methylation: methylcobalamin can act as a methyl donor. Biochemistry. 1991;30(32):8045-8051. doi:10.1021/bi00246a024</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi00246a024</ArticleId><ArticleId IdType="pubmed">1868079</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe T, Kaji R, Oka N, Bara W, Kimura J. Ultrahigh-dose methylcobalamin promotes nerve regeneration in experimental acrylamide neuropathy. J Neurol Sci. 1994;122(2):140-143. doi:10.1016/0022-510X(94)90290-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(94)90290-9</ArticleId><ArticleId IdType="pubmed">8021696</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada K, Tanaka H, Temporin K, et al. . Methylcobalamin increases Erk1/2 and Akt activities through the methylation cycle and promotes nerve regeneration in a rat sciatic nerve injury model. Exp Neurol. 2010;222(2):191-203. doi:10.1016/j.expneurol.2009.12.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2009.12.017</ArticleId><ArticleId IdType="pubmed">20045411</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7(11):639-649. doi:10.1038/nrneurol.2011.153</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.153</ArticleId><ArticleId IdType="pubmed">21989247</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Macdonald-Wallis C, Gray E, et al. . Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84(22):2247-2257. doi:10.1212/WNL.0000000000001642</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001642</ArticleId><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>Boylan KB, Glass JD, Crook JE, et al. . Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2013;84(4):467-472. doi:10.1136/jnnp-2012-303768</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-303768</ArticleId><ArticleId IdType="pubmed">23117489</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard SR, Wuu J, Cardoso M, et al. . Urinary p75ECD: a prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology. 2017;88(12):1137-1143. doi:10.1212/WNL.0000000000003741</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003741</ArticleId><ArticleId IdType="pmc">PMC5373786</ArticleId><ArticleId IdType="pubmed">28228570</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuwirth C, Barkhaus PE, Burkhardt C, et al. . Tracking motor neuron loss in a set of six muscles in amyotrophic lateral sclerosis using the Motor Unit Number Index (MUNIX): a 15-month longitudinal multicentre trial. J Neurol Neurosurg Psychiatry. 2015;86(11):1172-1179. doi:10.1136/jnnp-2015-310509</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-310509</ArticleId><ArticleId IdType="pubmed">25935892</ArticleId></ArticleIdList></Reference><Reference><Citation>Valentino F, Bivona G, Butera D, et al. . Elevated cerebrospinal fluid and plasma homocysteine levels in ALS. Eur J Neurol. 2010;17(1):84-89. doi:10.1111/j.1468-1331.2009.02752.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2009.02752.x</ArticleId><ArticleId IdType="pubmed">19659753</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci. 2019;13:1310. doi:10.3389/fnins.2019.01310</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>